Treatment of monomorphic B‐cell lymphoma with rituximab after liver transplantation in a child

Bueno, Javier; Ramil, Carmen; Argibay, Iván Somoza; Sanchez-Galindo, Amelia C; Solar, Alfonso; Arnal, F; Alvarez, Augusto; Sánchez-Mozo, Pilar; Gómez, Manuel

doi:10.1034/j.1399-3046.2003.00024.x

Cited by 13 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of these cases have been for treatment of humoral rejection (20,21,23,24,31) in different solid organ transplants, either alone, or in combination therapy with cyclophosphamide (24), Thymoglobulin (20) or plasmapharesis and IVIG (33). There have been no controlled studies of the safety or efficacy of Rituximab for treatment of graft rejection in pediatric patients, most of the experience in children resulting from treatment of lymphoma (55)(56)(57)(58)(59), and a single publication of a nonrandomized study in pediatric liver transplant rejection (59).…”

Section: Discussionmentioning

confidence: 99%

A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation

Zarkhin¹,

Li²,

Kambham

et al. 2008

American Journal of Transplantation

132

113

View full text Add to dashboard Cite

We report 1-year outcomes of a randomized study of Rituximab versus standard-of-care immunosuppression (Thymoglobulin and/or pulse steroids) for treatment of biopsy confirmed, acute transplant rejection with B-cell infiltrates, in 20 consecutive recipients (2-23 years). Graft biopsies, with Banff and CADI scores, CD20 and C4d stains, were performed at rejection and 1 and 6 months later. Peripheral blood CMV, EBV and BK viral loads, graft function, DSA, immunoglobulins, serum humanized antichimeric antibody (HACA) and Rituximab, and lymphocyte counts were monitored until 1 year posttreatment. Rituximab infusions were given with a high index of safety without HACA development and increased infections complications. Rituximab therapy resulted in complete tissue B-cell depletion and rapid peripheral B-cell depletion. Peripheral CD19 cells recovered at a mean time of ∼12 months. There were some benefits for the recovery of graft function (p = 0.026) and improvement of biopsy rejection scores at both the 1-(p = 0.0003) and 6-month (p < 0.0001) follow-up biopsies. Reappearance of C4d deposition was not seen on follow-up biopsies after Rituximab therapy, but was seen in 30% of control patients. There was no change in DSA in either group, independent of rejection resolution. This study reports safety and suggests further investigation of Rituximab as an adjunctive treatment for B-cell-mediated graft rejection.

show abstract

Section: Discussionmentioning

confidence: 99%

A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation

Zarkhin¹,

Li²,

Kambham

et al. 2008

American Journal of Transplantation

132

113

View full text Add to dashboard Cite

show abstract

“…In addition, the second child received high‐dose steroids for her ocular disease and steroids are a mainstay of chemotherapy for lymphomatous PTLD (1). Finally, she received rituximab, reported to be efficacious in PTLD treatment (24–27).…”

Section: Discussionmentioning

confidence: 99%

Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients

Traum

Rodig

Pilichowska

et al. 2006

Pediatric Transplantation

View full text Add to dashboard Cite

Post-transplant lymphoproliferative disorder (PTLD) is a complication of transplantation resulting from impaired immune surveillance because of pharmacologic immunosuppression. We present two cases of central nervous system (CNS) PTLD in children on calcineurin-inhibitor free immunosuppression with dramatically different presentations and outcomes. One patient had brain and spinal cord lymphoma with a rapid and fatal course. The other patient had brain and ocular PTLD that responded to multimodal therapy with reduction of immunosuppression, high-dose steroids, and rituximab given in a dose-escalation protocol. This protocol may have enhanced the penetration of rituximab into the CNS. We review the literature on CNS and ocular PTLD and elaborate on the treatments available for both diseases.

show abstract

“…Many more case reports and case series of using rituximab in PTLD in various settings appeared in the literature in the next several years [67–86]. The cases include pediatric and adult PTLD patients who underwent solid organ or bone marrow transplantations and achieved excellent results with rituximab.…”

Section: Rituximab In Management Of Ptldmentioning

confidence: 99%

Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab

Svoboda¹,

Kotloff²,

Tsai³

2006

Transplant Int

View full text Add to dashboard Cite

Summary Post‐transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ and bone marrow transplantations. Rituximab (Rituxan, Mabthera), a chimeric monoclonal antibody to the CD20 antigen on the surface of B‐cell lymphocytes, has been used increasingly in the treatment of PTLD. Rituximab was initially approved for the treatment of low‐grade non‐Hodgkin lymphomas, but multiple case studies, retrospective analyses, and phase II trials demonstrate the benefit of rituximab in PTLD. This paper reviews the current data on rituximab and its promising role in the management of PTLD.

show abstract

Treatment of monomorphic B‐cell lymphoma with rituximab after liver transplantation in a child

Cited by 13 publications

References 24 publications

A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation

A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation

Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients

Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab

Contact Info

Product

Resources

About